Suzette Delaloge

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +16

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Lionel Apétoh, François Ghiringhelli, Antoine Tesnière et al. · Nature Medicine · 2007 · 3K citations

Life Sciences, Immunology, Oncology +16

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts et al. · New England Journal of Medicine · 2016 · 2.1K citations · Full text

Medicine, Genetics, Oncology +16

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Antonella Sistigu, Takahiro Yamazaki, Erika Vacchelli et al. · Nature Medicine · 2014 · 1K citations

Medicine, Cancer Biology, Oncology +12

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

Mark E. Robson, Nadine Tung, PierFranco Conte et al. · Annals of Oncology · 2019 · 760 citations · Full text

Medicine, Oncology, Pharmacotherapy +17